Inhibikase Therapeutics, Inc.

NasdaqCM:IKT 株式レポート

時価総額：US$177.4m

Inhibikase Therapeutics マネジメント

マネジメント 基準チェック /34

Inhibikase Therapeutics' CEO is Milton Werner, appointed in Jun 2010, has a tenure of 14.42 years. total yearly compensation is $811.43K, comprised of 62.9% salary and 37.1% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $2.35M. The average tenure of the management team and the board of directors is 10.3 years and 3.9 years respectively.

主要情報

Milton Werner

最高経営責任者

US$811.4k

報酬総額

CEO給与比率62.9%
CEO在任期間14.4yrs
CEOの所有権1.3%
経営陣の平均在職期間10.3yrs
取締役会の平均在任期間3.9yrs

経営陣の近況

Recent updates

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Jan 25
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Aug 26

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug 12

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

CEO報酬分析

Inhibikase Therapeutics の収益と比較して、Milton Werner の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$811kUS$510k

-US$19m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$744kUS$501k

-US$18m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$611kUS$455k

-US$15m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$961kUS$293k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$385kUS$293k

-US$6m

Sep 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$535kUS$452k

-US$2m

報酬と市場: Milton's total compensation ($USD811.43K) is below average for companies of similar size in the US market ($USD1.48M).

報酬と収益: Milton's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Milton Werner (60 yo)

14.4yrs

在職期間

US$811,429

報酬

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Milton Werner
CEO, President & Director14.4yrsUS$811.43k1.32%
$ 2.3m
Garth Lees-Rolfe
Chief Financial Officerless than a yearデータなし0%
$ 0
Surendra Singh
Head of Chemistry10.3yrsデータなしデータなし
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno dataデータなしデータなし
Dan Williams
Controllerno dataデータなしデータなし

10.3yrs

平均在職期間

経験豊富な経営陣: IKT's management team is seasoned and experienced (10.3 years average tenure).

取締役

名称ポジション在職期間報酬所有権
Milton Werner
CEO, President & Director14.4yrsUS$811.43k1.32%
$ 2.3m
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno dataデータなしデータなし
Dennis Berman
Independent Director3.9yrsUS$74.85k0%
$ 0
Kenneth Marek
Member of Scientific Advisory Boardno dataデータなしデータなし
Jeffrey Kordower
Member of Scientific Advisory Boardno dataデータなしデータなし
Pankaj Pasricha
Member of Scientific Advisory Boardno dataデータなしデータなし
Roy Freeman
Independent Director3.9yrsUS$65.85k0%
$ 0
Roberto Bellini
Chairmanless than a yearデータなし2.17%
$ 3.9m
Robert Hauser
Member of Scientific Advisory Boardno dataデータなしデータなし
Karl Kieburtz
Member of Scientific Advisory Boardno dataデータなしデータなし
Ted Dawson
Member of Scientific Advisory Boardno dataデータなしデータなし
Valina Dawson
Member of Scientific Advisory Boardno dataデータなしデータなし

3.9yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: IKT's board of directors are considered experienced (3.9 years average tenure).